PharmaVoice’s Post

How do you improve health equity and diversity in pharmaceutical research?

Is health care actually affordable to Americans? At the 2024 annual SCbio conference, panelists discussed the state of the health care system and why consumers believe it to be “unaffordable.” Insightful read by Krys Merryman below. South Carolina Hospital Association John Stanford Biotechnology Innovation Organization #healthcare #healthnews #affordablecare #affordablecareact #southcarolina #healthcaresolutions #healthcaresystem #healthcareindustry #pharma #pharmaceuticals #pharmaceuticalindustry #lifesciences

PwC projects an 8% rise in health care costs in 2025—the highest level in 13 years. "This near-record trend is driven by inflationary pressure, prescription drug spending, and behavioral health utilization," PwC states in this report 👉 https://pwc.to/3g52Sa9 As cost trends continue to increase, so does the pressure on benefits solutions to address health and well-being while containing costs. MOBE gets at both. Our innovative financial model saves an average of 7.5% in health care spending within a year while improving health outcomes. There are ways to address rising costs year after year. Learn more about how we can help 👉 https://bit.ly/3OBMEZg #HealthCare #HealthCareCosts #CostOfCare #HealthPlan

Expanding on our highlight of QALY within the pharmacy industry, ICER has always been the cornerstone of such benchmarks. When we look at the pharmaceutical industry and the drugs that are produced. We need to understand that the financial impact of drugs changes the quality of life these drugs seek to improve. How can teachers afford a drug that costs $100,000 per year. Or should drugs be approved knowing that the average american can't afford them? This article on basis of QALY can help understand why its important to understand this metric.

Balancing innovation with affordability is a tricky dance. It's fantastic to see research on drugs that could prevent Alzheimer's moving forward. But let's not forget the financial reality. Yes, producing a drug for $5 sounds amazing, but it doesn't cover the $30 billion in research needed to find new breakthroughs. How do we find the right balance between cost and innovation in healthcare? The Senate HELP Committee investigates why Novo Nordisk charges Americans with diabetes and obesity exorbitantly high prices for Ozempic and Wegovy. #Innovation #HealthcareResearch #AlzheimersPrevention #MedicalAdvancements #DrugDevelopment #AffordableHealthcare #ResearchFunding #Pharmaceuticals #FutureOfMedicine

Avoiding Weight-Loss Pitfalls: How Organizations Can Strengthen Their Medication Strategy: When used correctly, weight-loss medications, such as glucagon-like peptide-1 (GLP-1) medications, can be a tool to help reduce costs and provide clinical results. #finance #pharmacy #lifesciences

Thoughts on this? >> A new report questions whether digital diabetes programs are worth the cost >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #pharmaceutical #biotech

Eva Pharma & Eli Lilly's ongoing collaboration to provide affordable insulin in Egypt and Africa exemplifies the positive impact of such partnerships. In a first for Lilly, they're supplying their active pharmaceutical ingredient (API) for insulin at a significantly reduced price to Eva Pharma. This will allow Eva Pharma to formulate, fill, and finish insulin vials and cartridges in Africa, making them a trusted manufacturer of these life-saving products. Eva Pharma expects to reach an incredible one million people per year by 2030. This aligns perfectly with Lilly's 30x30 initiative, which aims to improve healthcare access for 30 million people in limited-resource settings annually by 2030.

U.S. drug shortages have reached their highest level in a decade, affecting all classes of medicines but particularly low-cost, widely used generics. In response to the growing public health threat, US Pharmacopeia, American Cancer Society Cancer Action Network (ACS CAN) convened a briefing on Capitol Hill to call for immediate, comprehensive action to address this crisis. In a new blog, USP’s Amy Sonderman shares a first-hand account about the briefing and its most profound takeaway—the urgent need for solutions now, more than ever. Visit https://ow.ly/hvvR50S304N for the story behind our nation’s ongoing drug shortages as told by the patients, clinicians, and health policy experts who participated at this event. #Repost to help encourage policymakers to act. And stay tuned for the release of our inaugural Annual Drug Shortage Report (coming soon). #DrugShortage #SupplyChain

EVA Pharma and Eli Lilly co-hosted a powerful panel at the #WorldHealthAssembly, emphasizing partnerships to enhance access, affordability, and quality of essential #NCD medications. With the rise of #cardiovasculardiseases, #diabetes, and #cancer, LMICs face significant challenges in providing life-saving treatments. Collaborative efforts among pharmaceutical companies, governments, and global organizations are key to driving innovation and strengthening healthcare systems in LMICs. EVA Pharma and Eli Lilly remain committed to delivering high-quality, affordable insulin in Egypt and across Africa. What steps can we take to ensure everyone has access to the medications they need? #WorldHealthAssembly #GlobalHealth #AccessToMedicine #AfricaCDC #RASLifeScienceSolutions #MarketIntelligence #CompetitiveIntelligence #BusinessDevelopment Detailed News: https://lnkd.in/gDukR9Zp Follow our page for more updates: https://lnkd.in/de5zNWmK